Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Ovarian Neoplasms × Enoxaparin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Venous Thrombosis 3 Venous Thromboembolism 3 Neoplasms 3 Pancreatic Neoplasms 2 Venous Thormboembolism 1 Thrombosis 1 Thromboembolism 1 Stroke 1 Soft Tissue Neoplasms 1 Sarcoma 1 Pulmonary Embolism 1 Ovarian Neoplasms 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma 1 Catheter-Related Infections 1 Carcinoma, Pancreatic Ductal 1

Interventions

Paclitaxel 80 Carboplatin 76 Bevacizumab 53 Gemcitabine 29 pembrolizumab 27 liposomal doxorubicin 27 Topotecan 22 olaparib 19 Taxes 17 niraparib 15 Docetaxel 15 Immunoglobulin G 14 Disulfides 14 Cyclophosphamide 14 Cisplatin 11 durvalumab 10 Nivolumab 9 Doxorubicin 8 Albumin-Bound Paclitaxel 8 sargramostim 7 rucaparib 7 fludarabine phosphate 7 fludarabine 7 pazopanib 6 epacadostat 6 avelumab 6 Trabectedin 6 Magnetic Resonance Spectroscopy 6 Ipilimumab 6 Interleukin-2 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00908960 2017-12-19

MicroTEC

Dana-Farber Cancer Institute

Phase 2 Completed

70 enrolled 9 charts

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡